MCID: DXR001
MIFTS: 37

Doxorubicin Induced Cardiomyopathy malady

Categories: Rare diseases, Cardiovascular diseases

Aliases & Classifications for Doxorubicin Induced Cardiomyopathy

About this section

Aliases & Descriptions for Doxorubicin Induced Cardiomyopathy:

Name: Doxorubicin Induced Cardiomyopathy 45

Classifications:



Summaries for Doxorubicin Induced Cardiomyopathy

About this section
MalaCards based summary: Doxorubicin Induced Cardiomyopathy is related to cardiomyopathy and cerebellar vermis medulloblastoma. An important gene associated with Doxorubicin Induced Cardiomyopathy is GATA4 (GATA Binding Protein 4), and among its related pathways are Physiological and Pathological Hypertrophy of the Heart and Syndecan-1-mediated signaling events. Affiliated tissues include breast, prostate and pituitary, and related mouse phenotypes are respiratory system and no phenotypic analysis.

Related Diseases for Doxorubicin Induced Cardiomyopathy

About this section

Graphical network of the top 20 diseases related to Doxorubicin Induced Cardiomyopathy:



Diseases related to doxorubicin induced cardiomyopathy

Symptoms for Doxorubicin Induced Cardiomyopathy

About this section

Drugs & Therapeutics for Doxorubicin Induced Cardiomyopathy

About this section

Drugs for Doxorubicin Induced Cardiomyopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 8)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Doxorubicinapproved, investigationalPhase 2, Phase 3158223214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
2
DoxilApproved June 1999Phase 2, Phase 3158231703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
3Antibiotics, AntitubercularPhase 2, Phase 35971
4Topoisomerase InhibitorsPhase 2, Phase 34081
5Anti-Bacterial AgentsPhase 2, Phase 39140
6
Cyclophosphamideapproved, investigationalPhase 2264350-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
7
PaclitaxelapprovedPhase 2262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
8Albumin-Bound PaclitaxelPhase 22621

Interventional clinical trials:

idNameStatusNCT IDPhase
1Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer PatientsRecruitingNCT02078388Phase 2, Phase 3
299mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast CancerNot yet recruitingNCT02677714Phase 2

Search NIH Clinical Center for Doxorubicin Induced Cardiomyopathy

Genetic Tests for Doxorubicin Induced Cardiomyopathy

About this section

Anatomical Context for Doxorubicin Induced Cardiomyopathy

About this section

MalaCards organs/tissues related to Doxorubicin Induced Cardiomyopathy:

33
Breast, Prostate, Pituitary, Heart, Lung, Bone, Endothelial

Animal Models for Doxorubicin Induced Cardiomyopathy or affiliated genes

About this section

MGI Mouse Phenotypes related to Doxorubicin Induced Cardiomyopathy:

38 (show all 20)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053888.7EGFR, EPOR, GATA4, MAPK14, MET
2MP:00030128.5CNR1, EGFR, EPOR, GATA4, HGF, MET
3MP:00053708.4EGFR, EPOR, GATA4, HGF, MAPK14, MET
4MP:00053818.2CNR1, ECE1, EGFR, EPHB2, GATA4, MET
5MP:00053798.2ECE1, EGFR, EPHB2, GATA4, MAPK14, MET
6MP:00053697.9DES, ECE1, EGFR, GATA4, MAPK14, MET
7MP:00107717.9CNR1, CSF3, ECE1, EGFR, GATA4, MAPK14
8MP:00053807.8ECE1, EGFR, EPOR, GATA4, HGF, MAPK14
9MP:00028737.7CNR1, ECE1, EGFR, EPOR, GATA4, MAPK14
10MP:00036317.3CNR1, ECE1, EGFR, EPHB2, EPOR, GATA4
11MP:00053847.2CNR1, DES, EGFR, EPHB2, EPOR, GATA4
12MP:00053767.2CNR1, DES, ECE1, EGFR, EPOR, GATA4
13MP:00053977.1CSF3, ECE1, EGFR, EPOR, GATA4, HGF
14MP:00053856.9DES, ECE1, EGFR, EPOR, GATA4, HGF
15MP:00053786.7CNR1, ECE1, EGFR, EPHB2, EPOR, GATA4
16MP:00107686.4CNR1, DES, ECE1, EGFR, EPHB2, EPOR

Publications for Doxorubicin Induced Cardiomyopathy

About this section

Articles related to Doxorubicin Induced Cardiomyopathy:

(show top 50)    (show all 129)
idTitleAuthorsYear
1
Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice. (26873966)
2016
2
Protective effect of Co-enzyme Q10 On doxorubicin-induced cardiomyopathy of rat hearts. (27087047)
2016
3
Matricellular protein CCN1 mediates doxorubicin-induced cardiomyopathy in mice. (27167338)
2016
4
Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy. (25660617)
2015
5
Astragalus polysaccharide improves cardiac function in doxorubicin-induced cardiomyopathy through ROS-p38 signaling. (26885153)
2015
6
Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. (25569804)
2015
7
A metabolomic study of rats with doxorubicin-induced cardiomyopathy and Shengmai injection treatment. (25938766)
2015
8
Potent Paracrine Effects of human induced Pluripotent Stem Cell-derived Mesenchymal Stem Cells Attenuate Doxorubicin-induced Cardiomyopathy. (26057572)
2015
9
Protective effect of cilostazol against doxorubicin-induced cardiomyopathy in mice. (26191652)
2015
10
Heart rate dynamics in doxorubicin-induced cardiomyopathy. (25798626)
2015
11
Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy. (26511374)
2015
12
Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. (24486195)
2014
13
Interrelation between Expression of ADAM 10 and MMP 9 and Synthesis of Peroxynitrite in Doxorubicin Induced Cardiomyopathy. (24244825)
2013
14
Manipulation of Cardiac PI3K/Akt Signaling by Apoptosis regulator through modulating IAP expression (ARIA) Regulates Cardiomyocyte Death during the Doxorubicin-induced Cardiomyopathy. (24338479)
2013
15
Antioxidant, lipid lowering, and membrane stabilization effect of sesamol against doxorubicin-induced cardiomyopathy in experimental rats. (24228260)
2013
16
Embryonic stem cells improve cardiac function in Doxorubicin-induced cardiomyopathy mediated through multiple mechanisms. (22449713)
2012
17
Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. (22465037)
2012
18
Inorganic nitrate therapy improves Doxorubicin-induced cardiomyopathy a new window for an affordable cardiovascular therapy for everyone? (21596235)
2011
19
Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation ofA mitochondrial function. (21094500)
2011
20
Potential biomarkers in mouse myocardium of doxorubicin-induced cardiomyopathy: a metabonomic method and its application. (22110719)
2011
21
Thrombopoietin protects against doxorubicin-induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks. (21330293)
2011
22
Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. (21946105)
2011
23
S-diclofenac protects against doxorubicin-induced cardiomyopathy in mice via ameliorating cardiac gap junction remodeling. (22039489)
2011
24
Diclofenac sodium, a nonselective nonsteroidal anti-inflammatory drug aggravates doxorubicin-induced cardiomyopathy in rats. (19920767)
2010
25
Involvement of advanced glycation end-products, pentosidine and N(epsilon)-(carboxymethyl)lysine, in doxorubicin-induced cardiomyopathy in rats. (20004697)
2010
26
Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect. (20543097)
2010
27
How to protect doxorubicin-induced cardiomyopathy in male albino rats? (20051877)
2010
28
CO liberated from a carbon monoxide-releasing molecule exerts a positive inotropic effect in doxorubicin-induced cardiomyopathy. (19935076)
2010
29
Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. (19010377)
2009
30
Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model. (18379782)
2009
31
Treatment with an adenoviral vector encoding hepatocyte growth factor mitigates established cardiac dysfunction in doxorubicin-induced cardiomyopathy. (18083897)
2008
32
Granulocyte colony-stimulating factor improves left ventricular function of doxorubicin-induced cardiomyopathy. (17334414)
2007
33
Preventive effect of erythropoietin on cardiac dysfunction in doxorubicin-induced cardiomyopathy. (16449733)
2006
34
Overexpression of Nd1, a novel Kelch family protein, in the heart of transgenic mice protects against doxorubicin-induced cardiomyopathy. (16952015)
2006
35
Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy. (16039240)
2005
36
Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. (16364871)
2005
37
Anti-oxidants and apoptosis: attenuation of doxorubicin induced cardiomyopathy by carvedilol. (15380672)
2004
38
Mechanical unloading improves intracellular Ca2+ regulation in rats with doxorubicin-induced cardiomyopathy. (15582323)
2004
39
Molecular biology of doxorubicin-induced cardiomyopathy. (19644577)
2002
40
Doxorubicin-induced cardiomyopathy. (10910374)
2000
41
Evaluation of cardiac adrenergic neuronal damage in rats with doxorubicin-induced cardiomyopathy using iodine-131 MIBG autoradiography and PGP 9.5 immunohistochemistry. (10901455)
2000
42
Protective effects of carvedilol against doxorubicin-induced cardiomyopathy in rats. (10503942)
1999
43
Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. (9848575)
1998
44
Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. (9038198)
1997
45
Contractile failure in chronic doxorubicin-induced cardiomyopathy. (9344758)
1997
46
Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin. (7831179)
1994
47
Etiology of sarcoplasmic reticulum calcium release channel lesions in doxorubicin-induced cardiomyopathy. (1314436)
1992
48
Case presentation of doxorubicin-induced cardiomyopathy: a short- and long-term side effect of pediatric cancer treatment. (1675089)
1991
49
Activity of receptors coupled to guanine nucleotide binding regulatory protein in doxorubicin induced cardiomyopathy. (1660348)
1991
50
Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. (1860214)
1991

Variations for Doxorubicin Induced Cardiomyopathy

About this section

Expression for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section
Search GEO for disease gene expression data for Doxorubicin Induced Cardiomyopathy.

Pathways for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section

Pathways related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

(show all 24)
idSuper pathwaysScoreTop Affiliating Genes
19.7GATA4, MAPK14
29.7HGF, MET
39.6EGFR, EPOR
49.5EGFR, MET
59.4GATA4, HGF, MET
69.2EGFR, HGF, MET
79.2EGFR, HGF, MET
89.2EGFR, HGF, MET
99.2EGFR, HGF, MET
108.8CSF3, HGF, MET
11
Show member pathways
8.8EGFR, EPOR, GATA4, MAPK14
128.7EGFR, HGF, MAPK14, MET
13
Show member pathways
8.4EGFR, EPHB2, EPOR, HGF, MET
14
Show member pathways
8.4CNR1, EGFR, HGF, MAPK14, MET
15
Show member pathways
8.3EGFR, EPHB2, HGF, MAPK14, MET
16
Show member pathways
8.2EGFR, EPHB2, EPOR, MAPK14, MET
178.0CSF3, EGFR, EPOR, HGF, MET
18
Show member pathways
7.9EGFR, EPHB2, EPOR, HGF, MAPK14, MET
19
Show member pathways
7.9EGFR, EPHB2, EPOR, HGF, MAPK14, MET
20
Show member pathways
7.9EGFR, EPHB2, EPOR, HGF, MAPK14, MET
21
Show member pathways
7.6EGFR, EPHB2, EPOR, GATA4, HGF, MAPK14
22
Show member pathways
7.1CSF3, EGFR, EPHB2, EPOR, HGF, MAPK14
23
Show member pathways
6.7CSF3, DES, EGFR, EPHB2, EPOR, HGF
24
Show member pathways
6.4CSF3, ECE1, EGFR, EPHB2, EPOR, HGF

GO Terms for genes affiliated with Doxorubicin Induced Cardiomyopathy

About this section

Biological processes related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cell morphogenesisGO:000090210.1HGF, MAPK14
2positive chemotaxisGO:00509189.9HGF, MET
3protein phosphorylationGO:00064688.6EGFR, EPHB2, MAPK14, MET
4positive regulation of transcription from RNA polymerase II promoterGO:00459448.4EGFR, GATA4, MAPK14, MET

Molecular functions related to Doxorubicin Induced Cardiomyopathy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein tyrosine kinase activityGO:00047139.2EGFR, EPHB2, MET

Sources for Doxorubicin Induced Cardiomyopathy

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet